Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “First-line Treatment Failure Nasopharyngeal Carcinoma”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Testing effectiveness (Phase 2)Study completedNCT00747799
What this trial is testing

Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Who this might be right for
Nasopharyngeal Neoplasms
Sun Yat-sen University 54
Testing effectiveness (Phase 2)Looking for participantsNCT07101744
What this trial is testing

Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial

Who this might be right for
Nasopharyngeal Carcinoma (NPC)First-line Treatment Failure Nasopharyngeal Carcinoma
Sun Yat-sen University 41
Testing effectiveness (Phase 2)UnknownNCT04586088
What this trial is testing

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

Who this might be right for
Nasopharyngeal CarcinomaRecurrent Nasopharyngeal CarcinomaMetastatic Nasopharyngeal Carcinoma+3 more
Sun Yat-sen University 58
Testing effectiveness (Phase 2)Active Not RecruitingNCT06414577
What this trial is testing

Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy

Who this might be right for
Nasopharyngeal Cancer
XIANG YANQUN 38